Australian Genomics Study Tracking Outcomes After Kidney or Kidney-Pancreas Transplant from Donors Aged 18 to 75

What this Trial Is About

Researchers are conducting the Australian Genomics of Chronic Allograft Dysfunction AUSCAD study, a prospective observational study at Westmead Hospital. The study enrolls patients at the time of kidney or kidney-pancreas transplant to track their post-transplant outcomes. The main goal is to understand how gene expression and immune responses relate to important outcomes such as chronic rejection and graft loss. Participants include kidney or kidney-pancreas transplant recipients who are followed over time. The study collects data on risk factors and analyzes blood, urine, and kidney tissue samples. It is non-interventional, meaning no treatments are assigned by the study, and it observes natural outcomes and gene profiles. During the study, researchers monitor participants for graft failure, allograft rejection, and gene profiles at biopsy and follow-up visits up to about 60 months. Additional outcomes tracked include death, infections, malignancies, cardiovascular events, chronic allograft dysfunction, and other transplant-related complications. Participation involves regular clinical follow-up and sample collection to better understand transplant success and challenges.

Australian Genomics Of Chronic Allograft Dysfunction Study